http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-0159640-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33c922e05f6133b7d72dbb849d77487d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
filingDate 1995-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 1998-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d1efe902b15f529b257ae4a3f3dbe6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6b788f412e1f7c63a32d49ffc748d7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_243bf0c156f84b86419b77926dd51e7a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0c90304e4db1c41e8ae65a3c51300df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c06c3ebf387ae81c322fc80a88a76ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16d357aabe665fd9c9ea13ab1e99c7df
publicationDate 1998-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber KR-0159640-B1
titleOfInvention Ophthalmic Formulation for the Treatment of Myopia and Glaucoma Including Dopamine Receptor Stimulant
abstract The present invention relates to an ophthalmic body type for treating myopia and glaucoma including a dopamine receptor stimulant, wherein the ophthalmic formulation including the dopamine receptor stimulant and a cyclodextrin or a derivative thereof is controlled at the physiological pH of the eye to stimulate the eye. When the eyedrops are administered, the transition to the plasma is small and the transition to eye tissues such as the retina is excellent. Therefore, the eyedrops can be used more effectively in the treatment of myopia and glaucoma.
priorityDate 1995-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426208976
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID122143
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54562
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31101
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419540045
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591227
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419593433
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493269
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419583841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426122189
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10239
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415822015
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444041
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425165935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID28864
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID47811
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918447
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503384
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14049689
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444913
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493138
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450770914
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5287407
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23663392
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID838
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553698
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6005

Total number of triples: 50.